11th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium
Learning Objectives
Describe classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6th World Symposium, as well as the treatment options with respect to PAH-specific therapies
Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy
Identify various PH subtypes and explain their diagnosis and clinical course, particularly PH associated the hematologic disorders and portopulmonary hypertension
Describe the importance of screening for CTEPH and referral for definitive therapy, as well as gain knowledge on new developments in the field of CTEPH
Identify the role of clinical trials in the development of new PAH therapies, with a particular appreciation of the patient perspective as a clinical trial subject
describe the importance of screening for CTEPH and referral for definitive therapy, as well as gain knowledge on new developments in the field of CTEPH
Express how the evolving field of precision medicine applies to the current and future state of PAH diagnosis and treatment
Recognize the importance of nonpharmacologic interventions such as cardiac/pulmonary rehab.
Available Credit
- 6.50 ACPE - Pharmacist
- 6.50 AMA PRA Category 1 Credit(s)™
- 6.50 ANCC
- 6.50 Attendance